VX-659 + Tezacaftor + Ivacaftor - A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
Chicago Clinical Research 1304, N Central Ave, IL USA
dinesh@cloudbyz.com (422) 776-6909
